Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework. (PubMed, Front Oncol) - Sep 24, 2026 - "Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival (EFS), with a modest but clinically meaningful overall survival (OS) benefit at five years...For tumors harboring actionable oncogenic alterations, upfront resection followed by adjuvant targeted therapy remains the preferred strategy, whereas definitive chemoradiotherapy followed by consolidation durvalumab remains standard of care for unresectable stage III disease...Major uncertainties persist regarding the comparative efficacy of perioperative versus neoadjuvant-only strategies, the contribution of adjuvant immunotherapy, and the role of biomarker-guided treatment adaptation. This clinical framework provides structured guidance to support treatment selection across the heterogeneous spectrum of stage III disease, while recognizing that prospective validation of risk-adapted strategies remains essential."
IO biomarker • Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|